NEWS & EVENTS

Catalent and Humanigen today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab.

Catalent today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Catalent today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.

Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.

Catalent today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.

Catalent today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.

Catalent will continue to put our hearts into making our communities better through our programs promoting diversity & inclusion and corporate responsibility.